Safety, Tolerability, Immunogenicity and Efficacy of Multiple PolyPEPI1018 Vaccinations as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2018
At a glance
- Drugs PolyPEPI 1018 (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; First in man
- Acronyms OBERTO
- Sponsors Treos Bio
- 22 Sep 2018 Planned number of patients changed from 10 to 15.
- 22 Sep 2018 Planned End Date changed from 21 Dec 2018 to 21 Dec 2019.
- 22 Sep 2018 Planned primary completion date changed from 9 Oct 2018 to 9 Apr 2019.